WPG Advisers’s Vor Biopharma VOR Stock Holding History

WPG Advisers’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$405	Buy	22 +1	+5%	+$15	﹤0.01%	1459
2026 Q1	$375	Buy	+21	New	+$296	﹤0.01%	1392

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

WPG Advisers's VOR Position: Q2 2026 in Review

WPG Advisers increased its Vor Biopharma (VOR) stake by 4.8% in Q2 2026, buying an estimated $15 and bringing the position to 22 shares worth $405. The position accounts for ﹤0.01% of the portfolio, ranked #1459.

WPG Advisers first reported a position in VOR in Q1 2026 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

WPG Advisers held 22 shares of Vor Biopharma worth $405 as of Q2 2026.
WPG Advisers bought 1 Vor Biopharma share in Q2 2026, an estimated $15.
Vor Biopharma made up ﹤0.01% of WPG Advisers's portfolio in Q2 2026, its #1459 holding.
WPG Advisers first reported a position in Vor Biopharma in Q1 2026 and has held it in 2 quarters since.
102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on WPG Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.